Pathology of presynaptic proteins in Alzheimer's disease: More than simple loss of terminals

Neurobiology of Aging

Volumn 24, Issue 8, 2003, Pages 1047-1062

  Honer, William G ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Dementia; Neuropathology; SNARE proteins; Synaptophysin

Indexed keywords

CHROMOGRANIN A; GLUTAMATE TRANSPORTER; MESSENGER RNA; NERVE PROTEIN; PROTEIN; RAB PROTEIN; SECRETOGRANIN II; SECRETONEURIN; SNARE PROTEIN; SYNAPTOPHYSIN; SYNAPTOSOMAL ASSOCIATED PROTEIN 25; SYNAPTOTAGMIN; SYNTAXIN;

ACUTE DISEASE; ALZHEIMER DISEASE; ANIMAL; BRAIN; BRAIN ATROPHY; BRAIN REGION; CAUDATE NUCLEUS; CELL LOSS; COGNITION; COGNITIVE DEFECT; CONFERENCE PAPER; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE MODEL; DISEASE SEVERITY; FRONTAL CORTEX; GRAY MATTER; HIPPOCAMPUS; HUMAN; IMMUNOREACTIVITY; METABOLISM; MOLECULAR BIOLOGY; NERVE ENDING; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; NONHUMAN; OBSERVATION; OCCIPITAL CORTEX; PATHOLOGY; PATHOPHYSIOLOGY; PRESYNAPTIC NERVE; PRIORITY JOURNAL; PROTEIN DEPLETION; SENILE PLAQUE; STAGING; SYNAPSE; SYNAPTOSOME; TEMPORAL LOBE; TRANSGENIC MOUSE; WHITE MATTER;

EID: 0344845129     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2003.04.005     Document Type: Conference Paper

References (55)

1. Arendt T. Alzheimer's disease as a disorder of mechanisms underlying structural brain self-organization. Neuroscience. 102:2001;723-765.
2. Arendt T. Disturbance of neuronal plasticity is a critical pathogenic event in Alzheimer's disease. Int. J. Dev. Neurosci. 19:2001;231-245.
3. Blennow K., Bogdanovic N., Alafuzoff I., Ekman R., Davidsson P. Synaptic pathology in Alzheimer's disease: relation to severity of dementia, but not to senile plaques, neurofibrillary tangles or the ApoE4 allele. J. Neural Trans. 103:1996;603-618.
4. Brown D.F., Risser R.C., Bigio E.H., Tripp P., Stiegler A., Welch E.et al. Neocortical synapse density and Braak stage in the Lewy body variant of Alzheimer disease: a comparison with classic Alzheimer disease and normal aging. J. Neuropathol. Exp. Neurol. 57:1998;955-960.
5. Brun A., Liu X., Erikson C. Synapse loss and gliosis in the molecular layer of the cerebral cortex in Alzheimer's disease and in frontal lobe degeneration. Neurodegeneration. 4:1995;171-177.
6. Callahan L.M., Vaules W.A., Coleman P.D. Progressive reduction of synaptophysin message in single neurons in Alzheimer disease. J. Neuropathol. Exp. Neurol. 61:2002;384-395.
7. Callahan L.M., Vaules W.A., Coleman P.D. Quantitative decrease in synaptophysin message expression and increase in cathepsin D message expression in Alzheimer disease neurons containing neurofibrillary tangles. J. Neuropathol. Exp. Neurol. 58:1999;275-287.
8. Clinton J., Blackman S.E.-A., Royston M.C., Roberts G.W. Differential synaptic loss in the cortex in Alzheimerr's disease: a study using archival material. NeuroReport. 5:1994;497-500.
9. Davidsson P., Blennow K. Neurochemical dissection of synaptic pathology in Alzheimer's disease. Int. Psychogeriatr. 10:1998;11-23.
10. Davidsson P., Jahn R., Bergquist J., Ekman R., Blennow K. Synaptotagmin, a synaptic vesicle protein, is present in human cerebrospinal fluid. Mol. Chem. Neuropathol. 27:1996;195-210.
11. Dessi F., Colle M.-A., Hauw J.-J., Duyckaerts C. Accumulation of SNAP-25 immunoreactive material in axons of Alzheimer's disease. NeuroReport. 8:1997;3685-3689.
12. Fukumoto H., Cheung B.S., Hyman B.T., Irizarry M.C. B-secretase protein and activity are increased in the neocortex in Alzheimer disease. Arch. Neurol. 59:2002;1381-1389.
13. Gabriel S.M., Haroutunian V., Powchik P., Honer W.G., Davidson M., Davies P.et al. Increased concentrations of presynaptic proteins in the cingulate cortex of schizophrenics. Arch. Gen. Psychiatry. 54:1997;559-566.
14. Heffernan J.M., Eastwood S.L., Nagy Z., Sanders M.W., McDonald B., Harrison P.J. Temporal cortex synaptophysin mRNA is reduced in Alzheimer's disease and is negatively correlated with the severity of dementia. Exp. Neurol. 150:1998;235-239.
15. Heindel W.C., Jernigan T.L., Archibald S.L., Achim C.L., Masliah E., Wiley C.A. The relationship of quantitative brain magnetic resonance imaging measures to neuropathologic indices of human immunodeficiency virus infection. Arch. Neurol. 51:1994;1129-1135.
16. Heinonen O., Lehtovirta M., Soininen H., Helisalmi S., Mannermaa A., Sorvari H.et al. Alzheimer pathology of patients carrying apolipoprotein E e4 allele. Neurobiol. Aging. 16:1995;505-513.
17. Heinonen O., Soininen H., Sorvari H., Kosunen O., Paljärvi L., Koivisto E.et al. Loss of synaptophysin-like immunoreactivity in the hippocampal formation is an early phenomena in Alzheimer's disease. Neuroscience. 64:1995;375-384.
18. Honer WG. Indications of abnormal connectivity in neuropsychiatric disorders in postmortem studies. In: Agam G, Belmaker RH, editors. The postmortem brain in psychiatric research. Boston: Kluwer Academic Publishers; 2002. p. 75-91.
19. Honer W.G., Dickson D.W., Gleeson J., Davies P. Regional synaptic pathology in Alzheimer's disease. Neurobiol. Aging. 13:1992;375-382.
20. Honer WG, Young C, Falkai P. Synaptic pathology. In: Harrison PJ, Roberts GW, editors. The neuropathology of schizophrenia. Oxford: Oxford University Press; 2000. p. 105-36.
21. Lassmann H., Weiler R., Fischer P., Bancher C., Jellinger K., Floor E.et al. Synaptic pathology in Alzheimer's disease: immunological data for markers of synaptic and large dense-core vesicles. Neuroscience. 46:1992;1-8.
22. Lippa C.F., Hamos J.E., Pulaski-Salo D., DeGennaro L.J., Drachman D.A. Alzheimer's disease and aging: effects on perforant pathway perikarya and synapses. Neurobiol. Aging. 13:1992;405-411.
23. Liu X., Erikson C., Brun A. Cortical synaptic changes and gliosis in normal aging, Alzheimer's disease and frontal lobe degeneration. Dementia. 7:1996;128-134.
24. Lue L.-F., Brachova L., Civin H., Rogers J. Inflammation, Aβ deposition, and neurofibrillary tangle formation as correlates of Alzheimer's disease neurodegeneration. J. Neuropathol. Exp. Neurol. 55:1996;1083-1088.
25. Lue L.-F., Brachova L., Civin W.H., Rogers J. Inflammation, Aβ deposition, and neurofibrillary tangle formation as correlates of Alzheimer's disease neurodegeneration. J. Neuropathol. Exp. Neurol. 55:1996;1083-1088.
26. Lue L.-F., Kuo Y.-M., Roher A.E., Brachova L., Shen Y., Sue L.et al. Soluble amyloid β peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am. J. Pathol. 155:1999;853-862.
27. Marksteiner J., Kaufmann W.A., Gurka P., Humpel C. Synaptic proteins in Alzheimer's disease. J. Mol. Neurosci. 18:2002;53-63.
28. Masliah E. Recent advances in the understanding of the role of synaptic proteins in Alzheimer's disease and other neurodegenerative disorders. J. Alzheimer Dis. 3:2001;121-129.
29. Masliah E., Alford M., DeTeresa R., Mallory M., Hansen L. Deficient glutamate transport is associated with neurodegeneration in Alzheimer's disease. Ann. Neurol. 40:1996;759-766.
30. Masliah E., Ellisman M., Carragher B., Mallory M., Young S., Hansen L.et al. Three-dimensional analysis of the relationship between synaptic pathology and neuropil threads in Alzheimer disease. J. Neuropathol. Exp. Neurol. 51:1992;404-414.
31. Masliah E., Fagan A.M., Terry R.D., DeTeresa R., Mallory M., Gage F.H. Reactive synaptogenesis assessed by synaptophysin immunoreactivity is associated with GAP-43 in the dentate gyrus of the adult rat. Exp. Neurol. 113:1991;131-142.
32. Masliah E., Honer W.G., Mallory M., Voight M., Kushner P., Hansen L.et al. Topographical distribution of synaptic-associated proteins in the neuritic plaques of Alzheimer's disease hippocampus. Acta Neuropathol. 87:1994;135-142.
33. Masliah E., Iwai A., Mallory M., Uéda K., Saitoh T. Altered presynaptic protein NACP is associated with plaque formation and neurodegeneration in Alzheimer's disease. Am. J. Pathol. 148:1996;201-210.
34. Masliah E., Mallory M., Alford M., DeTeresa R., Hansen L.A., McKeel D.W.et al. Altered expression of synaptic proteins occurs early during progression of Alzheimer's disease. Neurology. 56:2001;127-129.
35. Masliah E., Mallory M., Hansen L., DeTeresa R., Alford M., Terry R. Synaptic and neuritic alterations during the progression of Alzheimer's disease. Neurosci. Lett. 174:1994;67-72.
36. Masliah E., Terry R.D., Alford M., DeTeresa R., Hansen L.A. Cortical and subcortical patterns of synaptophysinlike immunoreactivity in Alzheimer's disease. Am. J. Pathol. 138:1991;235-246.
37. Masliah E., Terry R.D., DeTeresa R.M., Hansen L.A. Immunohistochemical quantification of the synapse-related protein synaptophysin in Alzheimer disease. Neurosci. Lett. 103:1989;234-239.
38. Masliah E., Terry R.D., Mallory M., Alford M., Hansen L.A. Diffuse plaques do not accentuate synapse loss in Alzheimer's disease. Am. J. Pathol. 137:1990;1293-1297.
39. Minger S.L., Honer W.G., Esiri M.M., McDonald B., Keene J., Nicoll J.A.R.et al. Synaptic pathology in prefrontal cortex is present only with severe dementia in Alzheimer's disease. J. Neuropathol. Exp. Neurol. 60:2001;929-936.
40. Mukaetova-Ladinska E.B., Garcia-Siera F., Hurt J., Gertz H.-J., Xuereb J.H., Hills R.et al. Staging of cytoskeletal and β-amyloid changes in human isocortex reveals biphasic synaptic protein response during progression of Alzheimer's disease. Am. J. Pathol. 157:2000;623-636.
41. Perdahl E., Adolfsson R., Alafuzoff I., Albert K., Nestler E., Greengard P.et al. Synapsin I (protein I) in different brain regions in senile dementia of Alzheimer type and in multiinfarct dementia. J. Neural Trans. 60:1984;133-141.
42. Samuel W., Alford M., Hofstetter C.R., Hansen L. Dementia with Lewy bodies versus pure Alzheimer disease: differences in cognition, neuropathology, cholinergic dysfunction, and synapse density. J. Neuropathol. Exp. Neurol. 56:1997;499-508.
43. Samuel W., Terry R.D., DeTeresa R., Butters N., Masliah E. Clinical correlates of cortical and nucleus basalis pathology in Alzheimer dementia. Arch. Neurol. 51:1994;772-778.
44. Selkoe D.J. Alzheimer's disease is a synaptic failure. Science. 298:2002;789-791.
45. Shimohama S., Kamiya, Taniguchi T., Akagawa K., Kimura J. Differential involvement of synaptic vesicle and presynaptic plasma membrane proteins in Alzheimer's disease. Biochem. Biophys. Res. Commun. 236:1997;239-242.
46. Simpson I.A., Chundu K.R., Davies-Hill T., Honer W.G., Davies P. Decreased concentrations of GLUT1 and GLUT3 glucose transporters in the brains of patients with Alzheimer's disease. Ann. Neurol. 35:1994;546-551.
47. Su J.H., Deng G., Cotman C.W. Transneuronal degeneration in the spread of Alzheimer's disease pathology: immunohistochemical evidence for the transmission of tau hyperphosphorylation. Neurobiol. Dis. 4:1997;365-375.
48. Sze C.-I., Bi H., Kleinschmidt-DeMasters B.K., Filley C.M., Martin L.J. Selective loss of exocytotic presynaptic vesicle proteins in Alzheimer's disease brains. J. Neurol. Sci. 175:2000;81-90.
49. Sze C.-I., Troncoso J.C., Kawas C., Mouton P., Price D.L., Martin L.J. Loss of the presynaptic vesicle protein synaptophysin in hippocampus correlates with cognitive decline in Alzheimer disease. J. Neuropathol. Exp. Neurol. 56:1997;933-944.
50. Terry R.D., Masliah E., Salmon D.P., Butters N., DeTeresa R., Hill R.et al. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann. Neurol. 30:1991;572-580.
51. Tiraboschi P., Hansen L.A., Alford M., Masliah E., Thal L.J., Corey-Bloom J. The decline in synapses and cholinergic activity is asynchronous in Alzheimer's disease. Neurology. 55:2000;1278-1283.
52. Wakabayashi K., Honer W.G., Masliah E. Synapse alterations in the hippocampal-entorhinal formation in Alzheimer's disease with and without Lewy body disease. Brain Res. 667:1994;24-32.
53. Weiler R., Lassmann H., Fischer P., Jellinger K., Winkler H. A high ration of chromogranin A to synaptin/synaptophysin is a common feature of brains in Alzheimer and Pick disease. FEBS Lett. 263:1990;337-339.
54. Wiley C.A., Masliah E., Morey M., Lemere C., DeTeresa R., Grafe M.et al. Neocortical damage during HIV infection. Ann. Neurol. 29:1991;651-657.
55. Yang L.-B., Li R., Meri S., Rogers J., Shen Y. Deficiency of complement defense protein CD59 may contribute to neurodegeneration in Alzheimer's disease. J. Neurosci. 20:2000;7505-7509.